{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:10Z","timestamp":1790162110855,"version":"4.1.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","award":["P50CA254865"],"award-info":[{"award-number":["P50CA254865"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["22-148-27IRG"],"award-info":[{"award-number":["22-148-27IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107955","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T23:10:14Z","timestamp":1758064214000},"page":"107955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4\/6 Inhibitors"],"prefix":"10.1016","volume":"221","author":[{"given":"Uriel","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-0326","authenticated-orcid":false,"given":"Thomas S.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-9035","authenticated-orcid":false,"given":"Akihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2025.107955_bib2","unstructured":"SEER*Explorer Application [Internet]. [cited 2023 Jun 1]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2."},{"issue":"15","key":"10.1016\/j.phrs.2025.107955_bib3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.2023.4342","article-title":"Screening for skin cancer: US preventive services task force recommendation statement","volume":"329","author":"Force USPST","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib4","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"23","key":"10.1016\/j.phrs.2025.107955_bib5","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1377\/hlthaff.2023.00767","article-title":"US cancer detection decreased nearly 9 percent during the first year of the COVID-19 pandemic","volume":"43","author":"Kim","year":"2024","journal-title":"Health Aff. [Internet]"},{"key":"10.1016\/j.phrs.2025.107955_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.107955_bib8","unstructured":"Bristol Myers Squibb - FDA Approves YERVOYTM (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer [Internet]. [cited 2023 Jul 2]. Available from: https:\/\/news.bms.com\/news\/details\/2011\/FDA-Approves-YERVOY-ipilimumab-for-the-Treatment-of-Patients-with-Newly-Diagnosed-or-Previously-Treated-Unresectable-or-Metastatic-Melanoma-the-Deadliest-Form-of-Skin-Cancer\/default.aspx."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib9","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1172\/JCI84236","article-title":"Cancer immunotherapy innovator James allison receives the 2015 Lasker\u223cDeBakey clinical medical research award","volume":"125","author":"Hurst","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.107955_bib10","first-page":"3","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Transpl. Rev."},{"issue":"Spec Feature","key":"10.1016\/j.phrs.2025.107955_bib11","first-page":"96","article-title":"Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"Spec Feature","key":"10.1016\/j.phrs.2025.107955_bib12","first-page":"180","article-title":"Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/23808993.2021.1976637","article-title":"Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen","volume":"6","author":"Katsandris","year":"2021","journal-title":"Expert Rev. Precis Med Drug Dev."},{"key":"10.1016\/j.phrs.2025.107955_bib14","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.107955_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2025.107955_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17_","key":"10.1016\/j.phrs.2025.107955_bib19","article-title":"Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III\u2013IV melanoma: primary results from RELATIVITY-098","volume":"43","author":"Long","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib20","article-title":"Exploiting RAS nucleotide cycling as a strategy for drugging RAS-Driven cancers","volume":"21","author":"Mattox","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10555-013-9433-9","article-title":"Targeting MAPK pathway in melanoma therapy","volume":"32","author":"Cheng","year":"2013","journal-title":"Cancer Metastas.. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem Pharm."},{"issue":"null","key":"10.1016\/j.phrs.2025.107955_bib24","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: current challenges and future prospect","volume":"10","author":"Mu\u00f1oz-Couselo","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib25","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jid.2016.05.098","article-title":"Phosphoproteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2\u03b1 kinase levels in NRAS(Q61) mutant cells","volume":"136","author":"Posch","year":"2016","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med"},{"issue":"17","key":"10.1016\/j.phrs.2025.107955_bib27","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","article-title":"Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies","volume":"72","author":"Sharma","year":"2012","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib29","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and binimetinib: first global approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107955_bib30","first-page":"14","article-title":"The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies","author":"Imani","year":"2024","journal-title":"Front Oncol. [Internet]"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11912-013-0336-2","article-title":"MEK inhibition in the treatment of advanced melanoma","volume":"15","author":"Salama","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF\u2013MEK\u2013ERK pathway in cancer therapy","volume":"283","author":"Montagut","year":"2009","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: first global approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.phrs.2025.107955_bib34","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-015-0477-8","article-title":"Cobimetinib: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-Mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.phrs.2025.107955_bib36","article-title":"DREAMseq: a phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)\u2014Final clinical results","volume":"43","author":"Atkins","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"17_","key":"10.1016\/j.phrs.2025.107955_bib37","article-title":"Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E\/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN)","volume":"42","author":"Robert","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib38","unstructured":"PDQ Adult Treatment Editorial Board. Melanoma Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. 2002."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2025.107955_bib40","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2025.107955_bib41","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107955_bib42","series-title":"Mechanisms of Drug Resistance in Melanoma BT - Mechanisms of Drug Resistance in Cancer Therapy","first-page":"91","author":"Winder","year":"2018"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1346-8138.15521","article-title":"Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma","volume":"47","author":"Takahashi","year":"2020","journal-title":"J. Dermatol."},{"issue":"17","key":"10.1016\/j.phrs.2025.107955_bib47","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib48","doi-asserted-by":"crossref","first-page":"9235638","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. Rigopoulou e","volume":"2020","author":"Ralli","year":"2020","journal-title":"Editor. J. Immunol. Res"},{"key":"10.1016\/j.phrs.2025.107955_bib49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: a comprehensive meta-analysis of randomized controlled trials","volume":"63","author":"Zhang","year":"2018","journal-title":"Int Immunopharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib50","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11864-022-01006-7","article-title":"BRAF inhibitor resistance in melanoma: mechanisms and alternative therapeutic strategies","volume":"23","author":"Chen","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib51","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/cancers12102801","article-title":"Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"issue":"MAR","key":"10.1016\/j.phrs.2025.107955_bib52","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front Oncol."},{"issue":"18","key":"10.1016\/j.phrs.2025.107955_bib53","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"issue":"33","key":"10.1016\/j.phrs.2025.107955_bib55","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","article-title":"Reactivation of Mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma","volume":"287","author":"Yadav","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib56","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib58","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107955_bib62","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib63","article-title":"778\u2005TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-na\u00efve unresectable or metastatic melanoma","volume":"11","author":"Olson","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2025.107955_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157347","article-title":"Lenvatinib or anti-VEGF in combination with anti\u2013PD-1 differentially augments antitumor activity in melanoma","volume":"8","author":"Tran","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.22.00221","article-title":"Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death Protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination","volume":"41","author":"Arance","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib68","doi-asserted-by":"crossref","first-page":"v561","DOI":"10.1093\/annonc\/mdz255.063","article-title":"Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: phase III LEAP-003 study","volume":"30","author":"Eggermont","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib71","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/cells12091316","article-title":"Rethinking oncologic treatment strategies with Interleukin-2","volume":"12","author":"Ko","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Molecular Cancer"},{"issue":"21","key":"10.1016\/j.phrs.2025.107955_bib73","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib74","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"7","key":"10.1016\/j.phrs.2025.107955_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/vaccines13070727","article-title":"Advances in oncolytic viral therapy in melanoma: a comprehensive review","volume":"13","author":"Garg","year":"2025","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib77","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.ijrobp.2021.10.184","article-title":"IGNYTE: a phase 1\/2 Multi-Cohort clinical trial of RP1 \u00b1 nivolumab in patients with Non-Small cell lung cancer and other solid tumors","volume":"112","author":"Emamekhoo","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib78","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.ijrobp.2021.12.025","article-title":"Safety and efficacy of RP1\u00a0+\u00a0Nivolumab in patients with Non-Melanoma skin cancer of the head and neck: results from IGNYTE phase 1\/2 Multi-Cohort clinical trial","volume":"112","author":"Niu","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"16_","key":"10.1016\/j.phrs.2025.107955_bib79","article-title":"A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician\u2019s choice in patients with advanced melanoma that has progressed on anti\u2013PD-1 and anti\u2013CTLA-4 therapy (IGNYTE-3)","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib80","article-title":"507\u2005A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors","volume":"9","author":"Middleton","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2025.107955_bib81","unstructured":"Definition of oncolytic herpes simplex virus-1 expressing anti-CTLA-4 antibody\/CD40L\/4\u20131BBL RP3 - NCI Drug Dictionary - NCI [Internet]. [cited 2025 Apr 7]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/804923."},{"key":"10.1016\/j.phrs.2025.107955_bib82","first-page":"207","article-title":"Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115","author":"Robert","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib83","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol"},{"issue":"23","key":"10.1016\/j.phrs.2025.107955_bib84","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/onc.2009.95","article-title":"Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice","volume":"28","author":"Goel","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib85","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1073\/pnas.0336397100","article-title":"Components of the rb pathway are critical targets of UV mutagenesis in a murine melanoma model","volume":"100","author":"Kannan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib86","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1755-148X.2010.00752.x","article-title":"Differential roles of the prb and Arf\/p53 pathways in murine naevus and melanoma genesis","volume":"23","author":"Ferguson","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib87","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic braf induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib88","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The requirement for cyclin d function in tumor maintenance","volume":"22","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib89","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-04-2970","article-title":"Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background","volume":"65","author":"Ackermann","year":"2005","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.phrs.2025.107955_bib90","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.18632\/oncotarget.26515","article-title":"The interplay of CDK4 and CDK6 in melanoma","volume":"10","author":"Kollmann","year":"2019","journal-title":"Oncotarget"},{"issue":"6577","key":"10.1016\/j.phrs.2025.107955_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib92","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/cells10061334","article-title":"CDK4\/6 inhibitors in melanoma: a comprehensive review","volume":"10","author":"Garutti","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib93","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1101\/gad.7.3.331","article-title":"Direct binding of cyclin d to the retinoblastoma gene product (pRb) and prb phosphorylation by the cyclin D-dependent kinase CDK4","volume":"7","author":"Kato","year":"1993","journal-title":"Genes Dev."},{"issue":"19","key":"10.1016\/j.phrs.2025.107955_bib94","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The Cell-Cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"Sheppard","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib95","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/35096061","article-title":"The INK4a\/ARF network in tumour suppression","volume":"2","author":"Sherr","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol. [Internet]"},{"key":"10.1016\/j.phrs.2025.107955_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112531","article-title":"Getting under the skin: the role of CDK4\/6 in melanomas","volume":"204","author":"Guo","year":"2020","journal-title":"Eur. J. Med Chem."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib97","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djn157","article-title":"Frequent p16-independent inactivation of p14ARF in human melanoma","volume":"100","author":"Freedberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib98","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/jid.2010.216","article-title":"High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma","volume":"130","author":"Jonsson","year":"2010","journal-title":"J. Invest Dermatol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib99","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1128\/MCB.22.2.644-656.2002","article-title":"Germ line transmission of the Cdk4R24C mutation facilitates tumorigenesis and escape from cellular senescence","volume":"22","author":"Rane","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"11\u201312","key":"10.1016\/j.phrs.2025.107955_bib100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.phrs.2025.107955_bib101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","article-title":"Requirement for CDK4 kinase function in breast cancer","volume":"9","author":"Yu","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib103","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.phrs.2025.107955_bib104","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41388-022-02243-8","article-title":"Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with pten loss","volume":"41","author":"Yoshida","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jcp.21791","article-title":"Nuclear cyclin D1: an oncogenic driver in human cancer","volume":"220","author":"KIM","year":"2009","journal-title":"J. Cell Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib106","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J. Mol. Med."},{"issue":"16","key":"10.1016\/j.phrs.2025.107955_bib107","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1101\/gad.1437206","article-title":"Malignant melanoma: genetics and therapeutics in the genomic era","volume":"20","author":"Chin","year":"2006","journal-title":"Genes Dev."},{"issue":"79","key":"10.1016\/j.phrs.2025.107955_bib108","doi-asserted-by":"crossref","first-page":"34990","DOI":"10.18632\/oncotarget.26204","article-title":"MEK\/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and \u2018wild type\u2019 melanomas","volume":"9","author":"Posch","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib109","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/2159-8290.CD-17-0745","article-title":"A preexisting rare PIK3CA(E545K) subpopulation confers clinical resistance to MEK plus CDK4\/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling","volume":"8","author":"Romano","year":"2018","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.phrs.2025.107955_bib110","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/MCB.00706-13","article-title":"The FBXO4 tumor suppressor functions as a barrier to braf V600E -Dependent metastatic melanoma","volume":"33","author":"Lee","year":"2013","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action May not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2025.107955_bib113","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin d as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib114","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib115","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-15-2931","article-title":"Induction of therapeutic senescence in Vemurafenib-Resistant melanoma by extended inhibition of CDK4\/6","volume":"76","author":"Yoshida","year":"2016","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.phrs.2025.107955_bib116","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen Receptor\u2013Positive, HER2-Negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107955_bib117","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107955_bib118","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib119","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2025.107955_bib121","unstructured":"Breast Cancer Treatment (PDQ\u00ae) - NCI [Internet]. [cited 2023 Jul 23]. Available from: https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-treatment-pdq#_1458_toc."},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.phrs.2025.107955_bib123","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med. [Internet]"},{"issue":"20","key":"10.1016\/j.phrs.2025.107955_bib124","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib125","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107955_bib126","unstructured":"Overview of toxicities associated with immune checkpoint inhibitors - UpToDate [Internet]. [cited 2025 Aug 17]. Available from: https:\/\/www.uptodate.com\/contents\/overview-of-toxicities-associated-with-immune-checkpoint-inhibitors."},{"issue":"36","key":"10.1016\/j.phrs.2025.107955_bib127","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.phrs.2025.107955_bib128","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol. [Internet]"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther. Adv. Med Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers15010141","article-title":"BRAF and MEK inhibitors and their toxicities: a Meta-Analysis","volume":"15","author":"Garutti","year":"2023","journal-title":"Cancers]"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib132","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib133","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib134","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.107955_bib135","unstructured":"Cell C.S., 1993 undefined. Mammalian G1 cyclins. Elsevier [Internet]. [cited 2025 Mar 4]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/0092867493906365."},{"key":"10.1016\/j.phrs.2025.107955_bib136","unstructured":"Cell C.S., 1994 undefined. G1 phase progression: cycling on cue. Elsevier [Internet]. [cited 2025 Mar 4]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/0092867494905401."},{"issue":"5293","key":"10.1016\/j.phrs.2025.107955_bib137","first-page":"1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science (1979)"},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax6352","article-title":"SLC36A1-mTORC1 signaling drives acquired resistance to CDK4\/6 inhibitors","volume":"5","author":"Yoshida","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.107955_bib139","doi-asserted-by":"crossref","unstructured":"Sherr C., development JRG and, 1995 undefined. Inhibitors of mammalian G1 cyclin-dependent kinases. scholar.archive.org [Internet]. [cited 2025 Mar 4]; Available from: https:\/\/scholar.archive.org\/work\/6awwrjusrndedf5s36kqbmymeq\/access\/wayback\/http:\/\/genesdev.cshlp.org\/content\/9\/10\/1149.full.pdf.","DOI":"10.1101\/gad.9.10.1149"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib140","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov. [Internet]"},{"issue":"21","key":"10.1016\/j.phrs.2025.107955_bib141","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clin. Cancer Res [Internet]"},{"issue":"16","key":"10.1016\/j.phrs.2025.107955_bib142","first-page":"2255","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2016","journal-title":"Oncogene 2017 3616 [Internet]"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib143","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccell.2016.07.003","article-title":"A Kinase-Independent function of CDK6 links the cell cycle to tumor angiogenesis","volume":"30","author":"Kollmann","year":"2016","journal-title":"Cancer Cell [Internet]"},{"issue":"24","key":"10.1016\/j.phrs.2025.107955_bib144","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/onc.2015.407","article-title":"CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation","volume":"35","author":"Tigan","year":"2016","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02980-2","article-title":"c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc\/miR-29b-3p\/CDK6 axis","volume":"11","author":"Ji","year":"2020","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.phrs.2025.107955_bib146","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen Receptor\u2013Positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib147","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"18","key":"10.1016\/j.phrs.2025.107955_bib148","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.4161\/15384101.2014.946841","article-title":"The CDK4\/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4\/6 complexes","volume":"13","author":"Paternot","year":"2014","journal-title":"Cell Cycle"},{"issue":"25","key":"10.1016\/j.phrs.2025.107955_bib149","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb2210","article-title":"Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4\/6 inhibition","volume":"6","author":"Fassl","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib150","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","volume":"14","author":"Dietrich","year":"2024","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib151","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","article-title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity","volume":"186","author":"Arora","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib152","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-10-2458","article-title":"Functional activation of the estrogen receptor-\u03b1 and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole","volume":"71","author":"Sabnis","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib153","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.phrs.2025.107955_bib154","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib156","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00540-5","article-title":"ATRX is a regulator of therapy induced senescence in human cells","volume":"8","author":"Kovatcheva","year":"2017","journal-title":"Nat. Commun"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib158","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical Cross-Resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib159","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-17-0699","article-title":"In vivo E2F reporting reveals efficacious schedules of MEK1\/2-CDK4\/6 targeting and mTOR-S6 resistance mechanisms","volume":"8","author":"Teh","year":"2018","journal-title":"Cancer Discov. [Internet]"},{"issue":"17","key":"10.1016\/j.phrs.2025.107955_bib160","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","article-title":"MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancer","volume":"24","author":"De Leeuw","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107955_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661737","article-title":"Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma","volume":"12","author":"Lelliott","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-55914-x","article-title":"Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors","volume":"16","author":"Kan","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib163","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000484167","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors in breast cancer and potential biomarkers of response","volume":"12","author":"Guarducci","year":"2017","journal-title":"Breast Care"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib164","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00002","article-title":"Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer","volume":"6","author":"Asghar","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib165","first-page":"1","article-title":"Determinants of response to CDK4\/6 inhibitors in the real-world setting","volume":"7","author":"Witkiewicz","year":"2023","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib166","article-title":"AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers","volume":"7","author":"Abu-Khalaf","year":"2023","journal-title":"NPJ Precis Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib167","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1078-0432.CCR-21-2498","article-title":"Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for Triple-Negative breast cancer","volume":"28","author":"Shi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"79","key":"10.1016\/j.phrs.2025.107955_bib168","doi-asserted-by":"crossref","first-page":"34990","DOI":"10.18632\/oncotarget.26204","article-title":"MEK\/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and \u2018wild type\u2019 melanomas","volume":"9","author":"Posch","year":"2018","journal-title":"Oncotarget"},{"issue":"56","key":"10.1016\/j.phrs.2025.107955_bib169","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107955_bib170","unstructured":"Ko L., development CPG&, 1996 undefined. p53: puzzle and paradigm. researchgate.net [Internet]. [cited 2025 Apr 14]; Available from: https:\/\/www.researchgate.net\/profile\/Carol-Prives\/publication\/14545487_p53_Puzzle_and_paradigm\/links\/64e798950453074fbdab9636\/p53-Puzzle-and-paradigm.pdf."},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib171","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib172","first-page":"275","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol. 2007 84 [Internet]"},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib173","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib174","doi-asserted-by":"crossref","first-page":"896","DOI":"10.18632\/oncoscience.256","article-title":"CDK4\/6 inhibitor: from quiescence to senescence","volume":"2","author":"Yoshida","year":"2015","journal-title":"Oncoscience"},{"issue":"505","key":"10.1016\/j.phrs.2025.107955_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7171","article-title":"MDM2 antagonists overcome intrinsic resistance to CDK4\/6 inhibition by inducing p21","volume":"11","author":"Vilgelm","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"7668","key":"10.1016\/j.phrs.2025.107955_bib176","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib177","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib178","first-page":"1","article-title":"Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4\/6 inhibition","volume":"11","author":"Stopfer","year":"2020","journal-title":"Nat. Commun. 2020 111 [Internet]"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib179","first-page":"1","article-title":"Harnessing the immunotherapeutic potential of CDK4\/6 inhibitors in melanoma: is timing everything?","volume":"6","author":"Lelliott","year":"2022","journal-title":"NPJ Precis. Oncol. 2022 61 [Internet]"},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib180","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","article-title":"CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory","volume":"11","author":"Lelliott","year":"2021","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib181","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of cdk4\/6 promotes cd8 t-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib182","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32433","article-title":"Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: a systematic review and meta-analysis","volume":"10","author":"Garutti","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib184","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/2326-6066.CIR-19-0743","article-title":"Activation of CD8+ t cells contributes to antitumor effects of CDK4\/6 inhibitors plus MEK inhibitors","volume":"8","author":"Teh","year":"2020","journal-title":"Cancer Immunol. Res [Internet]"},{"issue":"7686","key":"10.1016\/j.phrs.2025.107955_bib185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2017","journal-title":"Nat."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Molecular Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib187","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40257-024-00907-7","article-title":"Overcoming resistance mechanisms to melanoma immunotherapy","volume":"26","author":"Zheng","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib188","first-page":"744","article-title":"Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors","volume":"2","author":"Fenton","year":"2019","journal-title":"Cancer Drug Resist."},{"issue":"11","key":"10.1016\/j.phrs.2025.107955_bib189","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-24-0254","article-title":"Longitudinal genomic analysis to Fine-tune targeted therapy: results of the phase II LOGIC 2 trial in patients with BRAFV600-Mutant metastatic melanoma","volume":"31","author":"Dummer","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"12_ement_2","key":"10.1016\/j.phrs.2025.107955_bib190","article-title":"Abstract PR06: phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4\/6i) in patients with advanced solid tumors","volume":"14","author":"Sullivan","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2025.107955_bib191","doi-asserted-by":"crossref","first-page":"S1407","DOI":"10.1016\/j.annonc.2022.08.038","article-title":"LBA40 phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable\/metastatic, BRAF V600- or NRAS-mutant melanoma","volume":"33","author":"Lebbe","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib192","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-20-2821","article-title":"Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia\/Ib trial","volume":"27","author":"Patnaik","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in rb positive cytoplasmic cyclin e negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat. Commun."},{"issue":"6421","key":"10.1016\/j.phrs.2025.107955_bib194","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib195","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.phrs.2025.107955_bib196","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic Anti-Tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"issue":"21","key":"10.1016\/j.phrs.2025.107955_bib197","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.211053698","article-title":"Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging","volume":"98","author":"Krtolica","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107955_bib198","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ebiom.2019.01.056","article-title":"Senolytics and senostatics as adjuvant tumour therapy","volume":"41","author":"Short","year":"2019","journal-title":"EBioMedicine"},{"issue":"21","key":"10.1016\/j.phrs.2025.107955_bib199","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107955_bib200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040723","article-title":"Senolytics for cancer therapy: is all that glitters really gold?","volume":"13","author":"Carpenter","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.phrs.2025.107955_bib202","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J. Intern. Med."},{"issue":"10","key":"10.1016\/j.phrs.2025.107955_bib203","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","article-title":"Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL\u2013BAX interaction","volume":"14","author":"Saleh","year":"2020","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107955_bib204","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","article-title":"First-in-Human study with preclinical data of BCL-2\/ BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors","volume":"30","author":"Lakhani","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41514-024-00138-4","article-title":"Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients\u2019 treatment","volume":"10","author":"Lelarge","year":"2024","journal-title":"NPJ Aging"},{"issue":"2","key":"10.1016\/j.phrs.2025.107955_bib206","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13767","article-title":"Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age","volume":"22","author":"Islam","year":"2023","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107955_bib207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25453-2","article-title":"Long-term treatment with senolytic drugs dasatinib and quercetin ameliorates age-dependent intervertebral disc degeneration in mice","volume":"12","author":"Novais","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2025.107955_bib208","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41419-024-07284-3","article-title":"Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells","volume":"15","author":"Kim","year":"2024","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.phrs.2025.107955_bib209","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/stcltm\/szae053","article-title":"Glutaminase-1 inhibition alleviates senescence of Wharton\u2019s jelly-derived mesenchymal stem cells via senolysis","volume":"13","author":"Lee","year":"2024","journal-title":"Stem Cells Transl. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.107955_bib210","first-page":"A235","article-title":"P207\u2005Senolytic effects of telaglenastat, a glutaminase inhibitor, on senescent airway epithelial cells","volume":"78","author":"Gomes","year":"2023","journal-title":"Thorax"},{"issue":"6526","key":"10.1016\/j.phrs.2025.107955_bib211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.abb5916","article-title":"Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders","volume":"371","author":"Johmura","year":"2021","journal-title":"Science"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:47:26Z","timestamp":1772880446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":211,"alternative-id":["S1043661825003809"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107955","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4\/6 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107955"}}